OBJECTIVES: The aim of this study was to determine whether iron oxide particles targeted to oxidation-specific epitopes image atherosclerotic lesions. BACKGROUND: Oxidized low-density lipoprotein plays a major role in atherosclerotic plaque progression and destabilization. Prior studies indicate that gadolinium micelles labeled with oxidation-specific antibodies allow for in vivo detection of vulnerable plaques with magnetic resonance imaging (MRI). However, issues related to biotransformation/retention of gadolinium might limit clinical translation. Iron oxides are recognized as safe and effective contrast agents for MRI. Because the efficacy of passively targeted iron particles remains variable, it was hypothesized that iron particles targeted to oxidation-specific epitopes might increase the utility of this platform. METHODS: Lipid-coated ultra-small superparamagnetic iron particles (LUSPIOs) (<20 nm) and superparamagnetic iron particles (<40 nm) were conjugated with antibodies targeted to either malondialdehyde-lysine or oxidized phospholipid epitopes. All formulations were characterized, and their in vivo efficacy evaluated in apolipoprotein E deficient mice 24 h after bolus administration of a 3.9-mg Fe/kg dose with MRI. In vivo imaging data were correlated with the presence of oxidation-specific epitopes with immunohistochemistry. RESULTS: MRI of atherosclerotic lesions, as manifested by signal loss, was observed after administration of targeted LUSPIOs. Immunohistochemistry confirmed the presence of malondialdehyde-epitopes and iron particles. Limited signal attenuation was observed for untargeted LUSPIOs. Additionally, no significant arterial wall uptake was observed for targeted or untargeted lipid-coated superparamagnetic iron oxide particles, due to their limited ability to penetrate the vessel wall. CONCLUSIONS: This study demonstrates that LUSPIOs targeted to oxidation-specific epitopes image atherosclerotic lesions and suggests a clinically translatable platform for the detection of atherosclerotic plaque. Copyright Â
OBJECTIVES: The aim of this study was to determine whether iron oxide particles targeted to oxidation-specific epitopes image atherosclerotic lesions. BACKGROUND: Oxidized low-density lipoprotein plays a major role in atherosclerotic plaque progression and destabilization. Prior studies indicate that gadolinium micelles labeled with oxidation-specific antibodies allow for in vivo detection of vulnerable plaques with magnetic resonance imaging (MRI). However, issues related to biotransformation/retention of gadolinium might limit clinical translation. Iron oxides are recognized as safe and effective contrast agents for MRI. Because the efficacy of passively targeted iron particles remains variable, it was hypothesized that iron particles targeted to oxidation-specific epitopes might increase the utility of this platform. METHODS:Lipid-coated ultra-small superparamagnetic iron particles (LUSPIOs) (<20 nm) and superparamagnetic iron particles (<40 nm) were conjugated with antibodies targeted to either malondialdehyde-lysine or oxidized phospholipid epitopes. All formulations were characterized, and their in vivo efficacy evaluated in apolipoprotein E deficient mice 24 h after bolus administration of a 3.9-mg Fe/kg dose with MRI. In vivo imaging data were correlated with the presence of oxidation-specific epitopes with immunohistochemistry. RESULTS: MRI of atherosclerotic lesions, as manifested by signal loss, was observed after administration of targeted LUSPIOs. Immunohistochemistry confirmed the presence of malondialdehyde-epitopes and iron particles. Limited signal attenuation was observed for untargeted LUSPIOs. Additionally, no significant arterial wall uptake was observed for targeted or untargeted lipid-coated superparamagnetic iron oxide particles, due to their limited ability to penetrate the vessel wall. CONCLUSIONS: This study demonstrates that LUSPIOs targeted to oxidation-specific epitopes image atherosclerotic lesions and suggests a clinically translatable platform for the detection of atherosclerotic plaque. Copyright Â
Authors: K E Kellar; D K Fujii; W H Gunther; K Briley-Saebø; A Bjørnerud; M Spiller; S H Koenig Journal: J Magn Reson Imaging Date: 2000-05 Impact factor: 4.813
Authors: M E Kooi; V C Cappendijk; K B J M Cleutjens; A G H Kessels; P J E H M Kitslaar; M Borgers; P M Frederik; M J A P Daemen; J M A van Engelshoven Journal: Circulation Date: 2003-04-28 Impact factor: 29.690
Authors: Rikin A Trivedi; Jean-Marie U-King-Im; Martin J Graves; Justin J Cross; Jo Horsley; Martin J Goddard; Jeremy N Skepper; George Quartey; Elizabeth Warburton; Ilse Joubert; Liqun Wang; Peter J Kirkpatrick; John Brown; Jonathan H Gillard Journal: Stroke Date: 2004-05-27 Impact factor: 7.914
Authors: Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2011-08-10
Authors: Karen C Briley-Saebo; Tuyen Hoang Nguyen; Alexander M Saeboe; Young-Seok Cho; Sung Kee Ryu; Eugenia R Volkova; Eugenia Volkava; Stephen Dickson; Gregor Leibundgut; Philipp Wiesner; Philipp Weisner; Simone Green; Florence Casanada; Yury I Miller; Walter Shaw; Joseph L Witztum; Zahi A Fayad; Sotirios Tsimikas Journal: J Am Coll Cardiol Date: 2012-02-07 Impact factor: 24.094
Authors: A Millon; S D Dickson; A Klink; D Izquierdo-Garcia; J Bini; E Lancelot; S Ballet; P Robert; J Mateo de Castro; C Corot; Z A Fayad Journal: Atherosclerosis Date: 2013-03-26 Impact factor: 5.162